Interesting morning here. Every low life short seller MM is on L-2 molesting the ask trying to short and crash the stock but the longs are buying, and even PAUL moved his ask to $1, LMAO...
I started buying these early Christmas gifts already, and this price is steal of deal.
The so called bad news, is not really news, it just triggered a short MM raid that is failing. The good news I see is:
75% of the hospitalizations were in the Placebo group based on low dose for Bucillamine and 100% of the hospitalizations were from Placebo in the High dose Bucillamine trials.
"there were no deaths and four hospitalizations, of which three were from the placebo arm and one from the Bucillamine low dose group (300mg/day). No hospitalizations occurred in the Bucillamine large dose group (600mg/day), which was the dose suggested by the independent Data Safety Monitoring Board (“DSMB”) at the first interim analysis for the Post-dose selection phase of the Study. The one hospitalization event in the Bucillamine arm occurred in the low dose group (300mg/day), which was the dose abandoned after the first interim analysis per DSMB’s recommendation. Although the number of hospitalization events was small, it demonstrated a positive trend in the Post-dose selection phase of the Study. "
"However, based on preliminary analyses, the data demonstrated that for patients with oxygen saturation <96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation (SpO2)"
"Additional analyses of the Study data are ongoing, which could support certain strategic decisions on pursuing the development and commercialization of Bucillamine.
Based on the Study’s data analyzed to date, the Company is committed to advancing the clinical and commercial development of Bucillamine and is pursuing the following strategic initiatives"
They don't sound done to me. In fact they said:
Bucillamine 2.0: Reformulating Bucillamine in an intravenous and inhaled version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e. organ transplantation), acute respiratory distress syndrome, and potential medical countermeasures (i.e. terrorist attack with a biological, chemical, or radiological/nuclear material, or a naturally occurring emerging disease), that may come with regulatory incentives awarded by the FDA, such as emergency use authorization, orphan drug, fast track, and breakthrough therapy designations.
Pharmaceutical Partnerships: Work with interested pharmaceutical partners to pursue potential domestic and international regulatory approvals and new clinical studies for infectious, inflammatory and respiratory disorders.
Government Support: Seek out potential funding opportunities offered by, but not limited to, the Biomedical Advanced Research and Development Authority (BARDA), the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).
Bullish
